Tech Company Financing Transactions
ImmunoMet Funding Round
On 3/9/2016, ImmunoMet landed $5.2 million in Series A funding from Mirae Asset Venture Investment and private investors.
Transaction Overview
Company Name
Announced On
3/9/2016
Transaction Type
Venture Equity
Amount
$5,200,000
Round
Series A
Investors
Mirae Asset Venture Investment (Lead Investor) (Jae Kim)
Proceeds Purpose
The primary use of these proceeds will be to fund the Company's research and clinical development programs, establish its worldwide headquarters in Houston, TX, and for general corporate purposes.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 Holcombe Blvd.
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Website
Email Address
Overview
ImmunoMet Therapeutics is a development-stage biotechnology company, focused on the development of innovative oncology products to improve the quality of life and make a meaningful difference in the lives of cancer patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Cowen
Chief Financial Officer
Michael Bell
Chief Medical Officer
Marc Rudoltz
Vice President
Sanghee Yoo
VP - Operations
Steve Pondell
VP - R & D
Dean Welsch
Browse more venture capital transactions:
Prev: 3/9/2016: Quarterly venture capital transaction
Next: 3/9/2016: Exo venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs